ANXA2 and renal cell carcinoma: As for ANX2 expression, the metastasis-free rate in patients with ANX2-positive primary RCC was 63.0% over 5 years and 46.5% over 10 years; this rate was significantly lower than the 90.1% 5-year metastasis-free survival and 83.6% 10-year metastasis-free survival observed in patients with ANX2-negative primary RCC (P<0.0001) (Figure 3).